Form 4: Cytokinetics Executive Exercises Options and Sells Shares
SEC Form 4 Filing
Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, exercised stock options and sold shares on April 9, 2024.
Summary
- On April 9, 2024, Fady Ibraham Malik, the EVP of Research & Development at Cytokinetics, exercised non-qualified stock options to acquire 28,605 shares of common stock at a price of $6.67 per share.
- Simultaneously, Malik sold 28,605 shares at $74.31 per share and 4,000 shares at $74.32 per share.
- Following these transactions, Malik directly owns 138,567 shares of Cytokinetics common stock.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a standard disclosure of an executive exercising options and selling shares, which doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the buying and selling activities of company executives. It's common for executives to exercise stock options and sell shares for personal financial management.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding executive compensation and stock ownership.
Key Dates
| Date | Description |
|---|---|
| 03/23/2016 | Date the Non-Qualified Stock Option became exercisable |
| 02/23/2026 | Expiration date of the Non-Qualified Stock Option |
| 04/09/2024 | Date of the transaction: exercise of options and sale of shares |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.